IP Library Granted Patent US 8,207,149
Granted Patent B2
US 8,207,149 · App. 13/244,945 · Granted Jun 26, 2012

Method for treating secondary hyperparathyroidism in CKD

Assignees: Cytochroma, Inc.; Proventiv Therapeutics, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,207,149
App. No.
13/244,945
Granted
Jun 26, 2012
Kind
B2
Abstract

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

Claims (11)

1. A method of treating secondary hyperparathyroidism in Chronic Kidney Disease (CKD) Stage 3 or Stage 4 in a human patient, comprising administering to the patient an effective amount of a controlled release, oral dosage form of 25-hydroxyvitamin D to reduce the subject's serum parathyroid hormone level by at least 30% while safely raising serum total 25-hydroxyvitamin D.

2. The method of claim 1 , wherein the subject is vitamin D insufficient or vitamin D deficient.

3. The method of claim 2 , wherein said effective amount of the controlled release, oral dosage form of 25-hydroxyvitamin D is also effective to increase the subject's serum total 25-hydroxyvitamin D level to at least 30 ng/mL.

4. The method of claim 3 , wherein said effective amount of the controlled release, oral dosage form of 25-hydroxyvitamin D is also effective to increase the subject's serum total 25-hydroxyvitamin D level to a value in a range of 50 ng/mL to 90 ng/mL.

5. The method of claim 1 , wherein the subject's plasma intact parathyroid hormone level is reduced to the target range for the CKD Stage.

6. The method of claim 1 , wherein the 25-hydroxyvitamin D is selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D 3 , and a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .

7. The method of claim 6 , wherein the 25-hydroxyvitamin D is 25-hydroxyvitamin D 3 .

8. The method of claim 1 , comprising administering said oral dosage on a schedule of once per day.

9. The method of claim 8 , wherein the daily dose is in a range of 1 μg to 1000 μg.

10. The method of claim 1 , wherein the daily dose of 25-hydroxyvitamin D is in a range of 1 μg to 1000 μg.

11. The method of claim 1 , wherein the amount of 25-hydroxyvitamin D in the controlled release, oral dosage form is in a range of 1 μg to 1000 μg per unit dose.

Assignments (15)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2021
From: OPKO IRELAND GLOBAL HOLDINGS, LTD.
To: EIRGEN PHARMA LTD.
Reel/Frame 055765/0953 →
CONFIRMATORY PATENT RIGHTS AGREEMENT Recorded Jul 31, 2015
From: OPKO IP HOLDINGS II, INC.
To: OPKO IRELAND GLOBAL HOLDINGS, LTD.
Reel/Frame 036238/0486 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 31, 2015
From: CYTOCHROMA CAYMAN ISLANDS LTD.
To: OPKO IP HOLDINGS II, INC.
Reel/Frame 036224/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: PROVENTIV THERAPEUTICS, LLC
To: OPKO HEALTH, INC.
Reel/Frame 036225/0082 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 31, 2015
From: CYTOCHROMA INC.
To: CYTOCHROMA CAYMAN ISLANDS LTD.
Reel/Frame 036238/0359 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 31, 2015
From: OPKO HEALTH, INC.
To: OPKO RENAL, LLC
Reel/Frame 036243/0691 →
RELEASE OF SECURITY INTEREST Recorded Mar 4, 2013
From: COMERICA BANK, A TEXAS BANKING ASSOCIATION AND AUTHORIZED FOREIGN BANK UNDER THE BANK ACT (CANADA)
To: CYTOCHROMA INC.
Reel/Frame 029914/0404 →
RELEASE OF SECURITY INTEREST Recorded Mar 4, 2013
From: COMERICA BANK, A TEXAS BANKING ASSOCIATION AND AUTHORIZED FOREIGN BANK UNDER THE BANK ACT (CANADA)
To: PROVENTIV THERAPEUTICS , LLC
Reel/Frame 029914/0067 →
SECURITY AGREEMENT Recorded Aug 16, 2012
From: CYTOCHROMA INC., A CORPORATION EXISTING UNDER THE LAWS OF ONTARIO
To: COMERICA BANK, A TEXAS BANKING ASSOCIATION AND AUTHORIZED FOREIGN BANK UNDER THE BANK ACT (CANADA)
Reel/Frame 028801/0539 →
SECURITY AGREEMENT Recorded Aug 16, 2012
From: PROVENTIV THERAPEUTICS, LLC
To: COMERICA BANK, A TEXAS BANKING ASSOCIATION AND AUTHORIZED FOREIGN BANK UNDER THE BANK ACT (CANADA)
Reel/Frame 028802/0035 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER WITH RESPECTIVE FILING DATE AND ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 028418 FRAME 0540. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT APPLICATION NUMBER IS 13/244,945; ASSIGNEE'S CORRECT ADDRESS IS 100 ALLSTATE PARKWAY, SUITE 600. Recorded Jul 3, 2012
From: TABASH, SAMIR P.; WHITE, JAY A.; AGUDOAWU, SAMMY
To: CYTOCHROMA INC.
Reel/Frame 028498/0028 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER AND RESPECTIVE FILING DATE PREVIOUSLY RECORDED ON REEL 028418 FRAME 0501. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT APPLICATION NUMBER IS 13/244,945. Recorded Jul 3, 2012
From: BISHOP, CHARLES W.
To: PROVENTIV THERAPEUTICS, LLC
Reel/Frame 028498/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2012
From: BISHOP, CHARLES W.
To: PROVENTIV THERAPEUTICS, LLC
Reel/Frame 028418/0501 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2012
From: MESSNER, ERIC J.
To: PROVENTIV THERAPEUTICS, LLC
Reel/Frame 028418/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2012
From: PETKOVICH, P. MARTIN
To: CYTOCHROMA INC.
Reel/Frame 028418/0445 →
Continuity (3)
Continuation 12109983 · Apr 25, 2008
Provisional Application 60913853 · Apr 25, 2007
Related Publication 20120015916A1 · Jan 19, 2012